CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
estradiol 0.045 mg/levonorgestrel 0.015mgdrug
Likely dose
estradiol 0.045 mg/levonorgestrel 0.015mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02475265
NCT02475265Phase 2Completed
CompareCT.gov

Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa

Massachusetts General Hospital·interventional·Posted Jun 18, 2015·Updated Jul 22, 2019

In Brief

A Phase 2 clinical trial evaluating estradiol 0.045 mg/levonorgestrel 0.015mg for Anorexia Nervosa and Osteoporosis. Completed, enrolled 11 participants across 1 site.

Detailed Summary

Decreased bone strength is a common and serious medical problem present in many women with anorexia nervosa. Women with decreased bone strength are more likely to suffer broken bones than women with normal bone strength. This study will investigate whether the use of transdermal estrogen can improve bone mineral density (BMD) and bone microarchitecture in women with anorexia nervosa anorexia nervosa when used for 6 months.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia Nervosa, Osteoporosis
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 18, 2015
Enrollment StartJul 1, 2015
Primary CompletionJun 27, 2018
Study CompletionJul 30, 2018
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 11.0 years ago

Interventions

estradiol 0.045 mg/levonorgestrel 0.015mgdrug